Cerapedics i-FACTOR yields 50% fusion rate vs. 20% for allograft at 1-year follow-up — 3 insights

Megan Wood -   Print  |

Mikkel O. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.

The study involved 98 patients aged 60 or older who suffered from lumbar spinal stenosis or concomitant degenerative olisthesis. The patients underwent non-instrumented lumbar posterolateral spine surgery with either i-FACTOR Peptide Enhanced Bone Graft or allograft.

Here are three insights.

1. At one-year postoperative follow-up, researchers found a 50 percent fusion rate using i-FACTOR versus a 20 percent fusion rate using allograft.

2. Those patients with one-level concomitant degenerative olisthesis accomplished estimated fusion rates of 40 percent with i-FACTOR compared to 21 percent with allograft.

3. Two-level concomitant degenerative olisthesis patients saw estimated fusion rates of 63 percent with i-FACTOR compared to 18 percent with allograft.

"These data indicate that i-FACTOR Peptide Enhanced Bone Graft offers significant potential benefits in fusion rates compared to allograft," said Dr. Andersen.

More articles on biologics:
3 things to know about Burst Biologics
Patients duped by non-FDA approved stem cell marketing: 8 things to know
Crowdfunding for stem cell treatments may spread misinformation: 4 insights


© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers